OSE Immunotherapeutics announces that the Independent Data Monitoring Committee (IDMC) has recommended to the trial’s steering committee that accrual of the Tedopi® Phase 3 trial for the treatment of advanced non-small cell lung cancer (NSCLC) could resume with a specified new recruitment strategy focused on a subgroup of patients who have failed a previous treatment with PD-1/PD-L1 immune checkpoint inhibitors (ICI).

MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company today announced that first patient has been dosed in its pivotal Phase 3 clinical trial assessing the safety and efficacy of MC2-01 Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) compared to MC2-01 vehicle and an active comparator for the treatment of plaque psoriasis in adult patients.

More Articles ...